A recent FiercePharma article discussed the massive settlement Bausch Health will pay for actions aimed at protecting their diabetes medication Glumetza. The Canadian drugmaker will pay $300 million for a 2019 lawsuit that claims the company paid off generic rivals so that the company could increase prices 800% for their type 2 diabetes drug. The class action lawsuit was driven by direct purchasers of the medication, and was set to go to trial in October.
Bausch to Dish Out $300M in Pay-to-Delay Settlement
The lawsuit claimed the company paid off generic rivals, allowing the company to increase prices 800%.
Sep 17, 2021
Recommended
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
